Galmed Pharmaceuticals(GLMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

GLMD Galmed Pharmaceuticals

Pre-Mkt 01-13 05:30:28 EST

0.8355

+0.0025

+0.30%

High0.8448	Low0.8120	Vol42.65K
Open0.8320	D1 Closing0.8330	Amplitude3.94%
Mkt Cap4.58M	Tradable Cap1.68M	Total Shares5.48M
T/O35.62K	T/O Rate2.12%	Tradable Shares2.02M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"GLMD","market":"US","secType":"STK","nameCN":"Galmed Pharmaceuticals","latestPrice":0.8355,"timestamp":1768251600000,"preClose":0.833,"halted":0,"volume":42650,"delay":0,"floatShares":2015100,"shares":5479231,"eps":-3.44,"marketStatus":"Pre-Mkt","change":0.0025,"latestTime":"01-13 05:30:28 EST","open":0.832,"high":0.8448,"low":0.812,"amount":35618.92572,"amplitude":0.039376,"askPrice":0.9604,"askSize":100,"bidPrice":0.82,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-3.44,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1768314600000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1394683200000,"exchange":"NASDAQ","adjPreClose":0.8355,"postHourTrading":{"tag":"盘后","latestPrice":0.8355,"preClose":0.8355,"latestTime":"19:46 EST","volume":43,"amount":36.1975,"timestamp":1768265167736},"volumeRatio":0.46322443360581594,"impliedVol":0.7031,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/GLMD","defaultTab":"news","newsList":[{"id":"2589355645","title":"Galmed Pharmaceuticals Announces Phase 1/2 Study of Aramchol and Regorafenib in Liver Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2589355645","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589355645?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:30","pubTimestamp":1765200641,"startTime":"0","endTime":"0","summary":"Galmed Pharmaceuticals Ltd. has announced the acceptance of a late-breaking abstract to be presented at the HEP-DART 2025 Meeting. The abstract is titled \"Targeting SCD1 enhances activity of standard of care regorafenib in hepatocellular carcinoma: translational rationale for a phase 1/2 study of the combination of Aramchol and regorafenib.\" The findings will be presented in a poster session on December 9, 2025, at 3pm . The study relates to the clinical development of Aramchol, Galmed's lead drug candidate, for use in combination therapy for hepatocellular carcinoma. Results have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galmed Pharmaceuticals Ltd. published the original content used to generate this news ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL4HGdDV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GLMD"],"gpt_icon":0},{"id":"2588882233","title":"Galmed Announces Grant of New Use Patents for the Combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for Mash","url":"https://stock-news.laohu8.com/highlight/detail?id=2588882233","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588882233?lang=en_us&edition=fundamental","pubTime":"2025-12-04 21:33","pubTimestamp":1764855216,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nFWN3XA0NP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GLMD"],"gpt_icon":0},{"id":"2588882416","title":"Galmed Pharmaceuticals Granted New Patent for Combination of Aramchol and Rezdiffra (Resmetirom) for MASH Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2588882416","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588882416?lang=en_us&edition=fundamental","pubTime":"2025-12-04 21:30","pubTimestamp":1764855038,"startTime":"0","endTime":"0","summary":"Galmed Pharmaceuticals Ltd. has announced the grant of new use patents for the combination of its drug candidate Aramchol with Madrigal Pharmaceuticals' Rezdiffra  for the treatment of MASH. The new patent, recently granted in South Korea, adds to earlier patents already granted in the United States, Europe, Canada, and other jurisdictions, extending Aramchol's patent protection in the U.S. until July 2042. The company highlighted that this development strengthens its position in the emerging field of combination therapies for MASH, where Aramchol's safety and tolerability make it an ideal candidate for use alongside other drugs.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galmed Pharmaceuticals Ltd. published the original content u","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDL5nQlx0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","MDGL","BK4588","GLMD"],"gpt_icon":0},{"id":"2588877863","title":"Galmed Pharmaceuticals Reports Strong Cash Position and Expands Therapeutic Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2588877863","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588877863?lang=en_us&edition=fundamental","pubTime":"2025-12-01 21:31","pubTimestamp":1764595866,"startTime":"0","endTime":"0","summary":"Galmed Pharmaceuticals Ltd. announced that it ended the third quarter of 2025 with approximately $19.2 million in cash and reported having practically zero debt on its balance sheet. The company highlighted the expansion of its therapeutic focus beyond liver disease, citing new data that supports broader clinical development for Aramchol in oncology and cardiometabolic indications. Galmed stated that it remains financially strong and is committed to both short- and long-term value creation through scientific innovation and responsible financial management.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galmed Pharmaceuticals Ltd. published the original content used to generate this news brief via PR Newswire  on December 01, 2025, and ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL4gzfRB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GLMD"],"gpt_icon":0},{"id":"2586217257","title":"Galmed Pharmaceuticals Q3 EPS $(0.33) Beats $(0.54) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2586217257","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586217257?lang=en_us&edition=fundamental","pubTime":"2025-11-26 21:34","pubTimestamp":1764164068,"startTime":"0","endTime":"0","summary":"Galmed Pharmaceuticals (NASDAQ:GLMD) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.54) by 38.89 percent. This is a 85.71 percent increase over losses of $(2.31) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/49081988/galmed-pharmaceuticals-q3-eps-0-33-beats-0-54-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLMD"],"gpt_icon":0},{"id":"2586257470","title":"Galmed Pharmaceuticals Q3 2025 cash and equivalents up 25% to USD 19.2 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2586257470","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586257470?lang=en_us&edition=fundamental","pubTime":"2025-11-26 21:30","pubTimestamp":1764163829,"startTime":"0","endTime":"0","summary":"Galmed Pharmaceuticals Ltd. reported its financial results for the third quarter  and nine months  ended September 30, 2025. For Q3 2025, research and development expenses totaled 1.1 million, while general and administrative expenses were 1.0 million. Total operating expenses for the quarter amounted to 2.1 million. For the nine-month period, research and development expenses reached 2.8 million, and general and administrative expenses were 2.7 million. Total operating expenses for the nine months were 5.5 million. As of September 30, 2025, cash and cash equivalents, short-term deposits, restricted cash, and marketable debt securities totaled 19.2 million. This represents an increase of 25 percent compared to December 31, 2024. Financial income, net, for Q3 2025 was negative 0.2 million, and for the nine-month period, it was negative 0.5 million. For the nine months ended September 30, 2025, an impairment of associate of 0.5 million was recorded.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nNDL4cd8tc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLMD","BK4139"],"gpt_icon":0},{"id":"2586577572","title":"Press Release: Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2586577572","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586577572?lang=en_us&edition=fundamental","pubTime":"2025-11-26 21:30","pubTimestamp":1764163800,"startTime":"0","endTime":"0","summary":"TEL AVIV, Israel, Nov. 26, 2025 /PRNewswire/ --Galmed Pharmaceuticals Ltd.  , a clinical-stage biopharmaceutical company focused on liver, cardiometabolic, and gastrointestinal oncology indications, reports financial results for the three and nine months ended September 30, 2025 and recent developments.Financial Summary -- Third Quarter 2025 vs. Third Quarter 2024. -- Cash and cash equivalents, short term deposits, restricted cash and. marketable debt securities totaled approximately $19.2 million as of. September 30, 2025, compared to approximately $15.4 million at December. -- Net loss amounted to approximately $2.0 million, or $0.33 per share, for. the three months ended September 30, 2025, compared to a net loss of. approximately $1.9 million, or $2.31 per share, for the three months. -- Research and development expenses amounted to approximately $1.1 million. $0.7 million for the three months ended September 30, 2024. The increase. resulted primarily from clinical and pre-clinical","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","R","GLMD","BK4139","BK4232"],"gpt_icon":0},{"id":"2584963286","title":"Analysts Offer Insights on Healthcare Companies: Cartesian Therapeutics (RNAC) and Galmed Pharmaceuticals (GLMD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2584963286","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584963286?lang=en_us&edition=fundamental","pubTime":"2025-11-19 04:30","pubTimestamp":1763497819,"startTime":"0","endTime":"0","summary":"Analysts fell to the sidelines weighing in on Cartesian Therapeutics (RNAC – Research Report) and Galmed Pharmaceuticals (GLMD – Research Report) w...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-cartesian-therapeutics-rnac-and-galmed-pharmaceuticals-glmd-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-cartesian-therapeutics-rnac-and-galmed-pharmaceuticals-glmd-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLV","RNAC","XBI","BK4588","BK4137","BK4139","HCSG","LABU","LU0029874061.USD","LU0128526141.USD","GLMD","BK4581","BK4585"],"gpt_icon":0},{"id":"2584950244","title":"BUZZ-U.S. STOCKS ON THE MOVE-Warner Bros Discovery, Energizer Holdings, Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2584950244","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584950244?lang=en_us&edition=fundamental","pubTime":"2025-11-19 03:03","pubTimestamp":1763492594,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Warner Bros Discovery, Energizer Holdings, TargetEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News C","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nL6N3WU0LP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WBD","GLMD","MDT","LITE","MOH","LGN","HEPS","NET","HD","FCX","LU2404859741.USD","STRK","DECK","KR","NFE","DEC","GNPX","EQT","BK4141","BRBR","INTU","STUB","DD","AS","TGT","RIOT","VG","VNDA","CEVA","USAW.SI","OWL","AXTA","AII","IVVD","HON","OSIS","ARDT","IE00BHPRN162.USD"],"gpt_icon":1},{"id":"2584568239","title":"BUZZ-Galmed Pharma rises after positive results of liver drug formulation study","url":"https://stock-news.laohu8.com/highlight/detail?id=2584568239","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584568239?lang=en_us&edition=fundamental","pubTime":"2025-11-18 22:49","pubTimestamp":1763477378,"startTime":"0","endTime":"0","summary":"BUZZ-Galmed Pharma rises after positive results of liver drug formulation study** Shares of Israel-based drug developer Galmed Pharmaceuticals GLMD.O rise 7% to $1.13 ** Company says its experimental drug, aramchol meglumine, showed positive results in an early-stage study ** GLMD says aramchol meglumine granules are absorbed much better into the body than free acid tablets — about five times better for the 400 mg dose and three times better for the 200 mg dose** Company is testing its drug for the treatment of liver conditions, gastrointestinal cancers and cardiometabolic diseases** Up to last close, stock down 67.1% YTD   ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nL4N3WU104:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GLMD"],"gpt_icon":0},{"id":"2584955049","title":"Galmed Pharmaceuticals Shares Rise 7.4% After Co Reports Liver Drug Trial Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2584955049","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584955049?lang=en_us&edition=fundamental","pubTime":"2025-11-18 22:47","pubTimestamp":1763477245,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nFWN3WU10Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GLMD","BK4139"],"gpt_icon":0},{"id":"2584958358","title":"BRIEF-Galmed Announces Meaningful Top Line Results From Am-001 Study Of Aramchol Meglumine","url":"https://stock-news.laohu8.com/highlight/detail?id=2584958358","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584958358?lang=en_us&edition=fundamental","pubTime":"2025-11-18 21:38","pubTimestamp":1763473116,"startTime":"0","endTime":"0","summary":"BRIEF-Galmed Announces Meaningful Top Line Results From Am-001 Study Of Aramchol MeglumineGalmed Pharmaceuticals Ltd GLMD.O:GALMED ANNOUNCES MEANINGFUL TOP LINE RESULTS FROM AM-001 STUDY OF ARAMCHOL M","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nTUA25VNKT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GLMD"],"gpt_icon":0},{"id":"2584930787","title":"Galmed Reports Strong Bioavailability Results for Aramchol Meglumine in Phase 1 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2584930787","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584930787?lang=en_us&edition=fundamental","pubTime":"2025-11-18 21:30","pubTimestamp":1763472636,"startTime":"0","endTime":"0","summary":"Galmed Pharmaceuticals Ltd. has announced top-line results from its AM-001 Phase 1 bioavailability study of Aramchol meglumine. The study, which enrolled 30 healthy volunteers, compared the bioavailability of Aramchol meglumine granules to Aramchol free acid tablets. Findings indicate that Aramchol meglumine granules at doses of 400mg and 200mg demonstrated approximately 5-fold and 3-fold higher bioavailability, respectively, compared to the 300mg Aramchol free acid tablets. Based on these results, Galmed has identified a 400mg once-daily regimen as the optimal dose for future clinical trials. The company plans to advance Aramchol meglumine into Phase 2 oncology studies in the first half of 2026. Results from the AM-001 study have already been announced.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and sh","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDL1fQ0pH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GLMD"],"gpt_icon":0},{"id":"2584293076","title":"Galmed Pharmaceuticals- Top-Line Results Showed That Bioavailability of Aramchol Meglumine 400Mg and 200Mg Granules Is Considerably Greater","url":"https://stock-news.laohu8.com/highlight/detail?id=2584293076","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584293076?lang=en_us&edition=fundamental","pubTime":"2025-11-18 21:30","pubTimestamp":1763472603,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nTUA25VNKT:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GLMD","BK4139"],"gpt_icon":0},{"id":"2584629997","title":"Galmed Pharmaceuticals Reveals Promising Results in Oncology Drug Combination Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2584629997","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584629997?lang=en_us&edition=fundamental","pubTime":"2025-11-17 21:59","pubTimestamp":1763387988,"startTime":"0","endTime":"0","summary":"Galmed Pharmaceuticals ( ($GLMD) ) has shared an update. Galmed Pharmaceuticals announced on November 17, 2025, the top-line results of their oncol...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/galmed-pharmaceuticals-reveals-promising-results-in-oncology-drug-combination-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/galmed-pharmaceuticals-reveals-promising-results-in-oncology-drug-combination-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GLMD","BK4139"],"gpt_icon":0},{"id":"2584626078","title":"BRIEF-Galmed Announces Top-Line Results In Oncology MoA Studies A 3-Drug Combination Of Aramchol, Stivarga® And Metformin Significantly Enhanced Gi Tumor Cells, Killing In-Vivo And In-Vitro","url":"https://stock-news.laohu8.com/highlight/detail?id=2584626078","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584626078?lang=en_us&edition=fundamental","pubTime":"2025-11-17 21:39","pubTimestamp":1763386743,"startTime":"0","endTime":"0","summary":"BRIEF-Galmed Announces Top-Line Results In Oncology MoA Studies A 3-Drug Combination Of Aramchol, Stivarga And Metformin Significantly Enhanced Gi Tumor Cells, Killing In-Vivo And In-VitroGalmed Pharm","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nTUA6RMDYN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GLMD"],"gpt_icon":0},{"id":"2584462690","title":"Galmed Pharmaceuticals Unveils Promising Synergistic Results for Aramchol, Stivarga, and Metformin in GI Cancer Models","url":"https://stock-news.laohu8.com/highlight/detail?id=2584462690","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584462690?lang=en_us&edition=fundamental","pubTime":"2025-11-17 21:30","pubTimestamp":1763386255,"startTime":"0","endTime":"0","summary":"Galmed Pharmaceuticals Ltd. has announced top-line results from preclinical studies evaluating a three-drug combination of Aramchol, Stivarga , and metformin for gastrointestinal  cancers. The studies demonstrated a synergistic effect in enhancing GI tumor cell killing both in vivo and in vitro. Galmed reported that this combination has the potential to serve as a new fixed-dose treatment, which could extend the commercial lifecycle of Stivarga as its main patents are set to expire in Europe in August 2028 and in the U.S. in July 2032. New patent applications have been submitted to the USPTO. The company plans to initiate a Phase 1b clinical trial at Virginia Commonwealth University Massey Comprehensive Cancer Center in early 2026, targeting metastatic colorectal cancer, hepatocellular carcinoma, and cholangiocarcinoma, with a planned expansion cohort including metformin. The results from this clinical study have not yet been presented.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDLbJs73V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLMD","BK4139"],"gpt_icon":0},{"id":"2584662698","title":"Galmed Announces Top-Line Results in Oncology Moa Studies: a 3-Drug Combination of Aramchol, Stivarga® and Metformin Significantly Enhanced Gi Tumor Cells, Killing in-Vivo and in-Vitro","url":"https://stock-news.laohu8.com/highlight/detail?id=2584662698","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584662698?lang=en_us&edition=fundamental","pubTime":"2025-11-17 21:30","pubTimestamp":1763386201,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nTUA6RMDYN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GLMD","BK4139"],"gpt_icon":0},{"id":"2569115727","title":"Galmed Pharmaceuticals Ltd. Announces Proxy Proposals for Upcoming October 2025 Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2569115727","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569115727?lang=en_us&edition=fundamental","pubTime":"2025-09-23 23:23","pubTimestamp":1758641006,"startTime":"0","endTime":"0","summary":"Galmed Pharmaceuticals Ltd. is set to hold its Annual General Meeting of Shareholders on October 28, 2025, at Meitar Law Offices in Ramat Gan, Israel. Shareholders will vote on the proposals outlined in the Proxy Statement. The company's board of directors recommends that shareholders vote \"FOR\" all of the proposals on the agenda.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galmed Pharmaceuticals Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 19, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250923:nNDL3B52nY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GLMD"],"gpt_icon":0},{"id":"2568291847","title":"Galmed Pharmaceuticals Schedules Annual General Meeting for October 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2568291847","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568291847?lang=en_us&edition=fundamental","pubTime":"2025-09-20 04:27","pubTimestamp":1758313677,"startTime":"0","endTime":"0","summary":"Galmed Pharmaceuticals ( ($GLMD) ) has shared an announcement. Galmed Pharmaceuticals Ltd. announced that it will hold its Annual General Meeting o...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/galmed-pharmaceuticals-schedules-annual-general-meeting-for-october-2025?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/galmed-pharmaceuticals-schedules-annual-general-meeting-for-october-2025?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GLMD","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.galmedpharma.com","stockEarnings":[{"period":"1week","weight":-0.0083},{"period":"1month","weight":-0.2043},{"period":"3month","weight":-0.4198},{"period":"6month","weight":-0.6185},{"period":"1year","weight":-0.7119},{"period":"ytd","weight":0.1133}],"compareEarnings":[{"period":"1week","weight":0.0108},{"period":"1month","weight":0.0197},{"period":"3month","weight":0.0497},{"period":"6month","weight":0.1136},{"period":"1year","weight":0.1975},{"period":"ytd","weight":0.0194}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.","yearOnYearQuotes":[{"month":1,"riseRate":0.583333,"avgChangeRate":0.03863},{"month":2,"riseRate":0.454545,"avgChangeRate":-0.047865},{"month":3,"riseRate":0.272727,"avgChangeRate":-0.072855},{"month":4,"riseRate":0.5,"avgChangeRate":-0.013881},{"month":5,"riseRate":0.416667,"avgChangeRate":-0.089814},{"month":6,"riseRate":0.75,"avgChangeRate":0.160804},{"month":7,"riseRate":0.416667,"avgChangeRate":-0.094546},{"month":8,"riseRate":0.25,"avgChangeRate":-0.058125},{"month":9,"riseRate":0.5,"avgChangeRate":0.034812},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.138105},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.048693},{"month":12,"riseRate":0.416667,"avgChangeRate":0.037621}],"exchange":"NASDAQ","name":"Galmed Pharmaceuticals","nameEN":"Galmed Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Galmed Pharmaceuticals(GLMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Galmed Pharmaceuticals(GLMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Galmed Pharmaceuticals,GLMD,Galmed Pharmaceuticals股票,Galmed Pharmaceuticals股票老虎,Galmed Pharmaceuticals股票老虎国际,Galmed Pharmaceuticals行情,Galmed Pharmaceuticals股票行情,Galmed Pharmaceuticals股价,Galmed Pharmaceuticals股市,Galmed Pharmaceuticals股票价格,Galmed Pharmaceuticals股票交易,Galmed Pharmaceuticals股票购买,Galmed Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Galmed Pharmaceuticals(GLMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Galmed Pharmaceuticals(GLMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction